Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pan Malayan has received permission to market its one-dose prescription cream treatment for vaginal yeast infections, Gynazole-1, in Singapore. Pan Malayan has licensed the drug from KV Pharmaceutical.
Subscribe to our email newsletter
Pan Malayan plans to eventually market Gynazole-1 in a total of six countries in the Asian region.
Marc Hermelin, vice chairman and CEO of KV stated, “The Pan Malayan approval marks the first for Gynazole-1 in the Asian region, and Singapore is an ideal market in which to get started given its designation as a reference country within the region.”
Pan Malayan expects to begin introduction of the product, which will be marketed in Singapore as Gynafort, during the second half of the company’s current fiscal year.